Specialists gathered in Brazzaville at the end of March with a blunt message. Cervical cancer is rising in the Republic of Congo, and the country must lean harder into prevention before the disease takes a wider toll on its women.
A Warning From Brazzaville’s Health Specialists
The alert came on 28 March during a public health talk in the capital. Gynaecologist-obstetrician and public health specialist Dr Darius Eryx Mbou Essié told the audience that cancer cases are climbing across Congo, with cervical cancer among the most worrying.
He framed the trend as serious but far from hopeless. Caught early, he explained, the disease responds well to treatment. Pre-cancerous lesions can be managed at modest cost, often without the heavy interventions that advanced cases demand.
Why Early Detection Changes Everything
The doctor pointed to two affordable techniques already within reach. Cryotherapy and conisation can clear pre-cancerous lesions before they turn dangerous. Both work best when a woman is screened in time, long before symptoms appear.
The picture darkens for women diagnosed late. Dr Mbou Essié acknowledged that Congo’s health facilities cannot always handle advanced forms of the disease. Their treatment stays expensive and complex, a gap that prevention is meant to narrow.
That is why screening sits at the heart of the message. Specialists at the gathering described detection not as a luxury but as the cheapest, most reliable tool the health system currently has against a quiet and treatable threat.
Screening From Age 25
The campaigns now under way put women first. They urge regular check-ups starting at 25, an age when routine tests can catch trouble early enough to matter. Waiting, the specialists warned, only raises the stakes.
Two methods stand out for their accessibility. A cervical smear or a visual inspection of the cervix can both be performed in basic health structures across the country. Neither requires the kind of equipment that exists only in major hospitals.
The aim is to make these tests ordinary rather than exceptional. By bringing screening into everyday primary care, the specialists hope women will treat it as a habit, not a reaction to fear or visible illness.
The Risk Factors Behind the Numbers
The experts were direct about what fuels the disease. Early sexual activity, multiple partners and a reluctance to seek screening all raise the danger. These patterns help spread the human papillomavirus, known as HPV.
That virus is the central villain in this story. HPV drives most pre-cancerous lesions of the cervix, which is why public messaging keeps returning to it. Understanding the link, the specialists argued, is the first step toward changing behaviour.
There is a further complication. The specialists noted that HIV infection can deepen a woman’s vulnerability to HPV. It may also speed the slide from pre-cancerous changes toward cancer itself, layering one health challenge onto another.
Shared Responsibility, Public and Personal
Throughout the discussion, one theme returned often. Fighting cancer cannot fall to hospitals alone. The speakers called for a joint push from public authorities and civil society, each reinforcing the other’s reach.
Yet they refused to let individuals off the hook. Personal responsibility, they stressed, remains decisive. Lower-risk choices and regular screening are decisions a woman makes for herself, and they shape her odds long before any clinic gets involved.
This balance, between collective duty and private vigilance, defined the tone of the meeting. Awareness campaigns can inform, but only acted-upon knowledge protects. The specialists wanted both halves of that equation taken seriously.
A System Slowly Opening Up
Beyond the warnings, there were signs of progress. Screening and treatment of pre-cancerous lesions are being folded into the care package of the universal health insurance fund (Caisse d’assurance maladie universelle), a notable step.
The change matters most for those with the least. By covering these services, the scheme widens access for vulnerable populations who might otherwise skip a test they cannot afford. For many women, cost has long been the deciding barrier.
It signals a quiet shift in how Congo approaches the disease. Prevention is moving from advice offered at public talks toward a service the system itself is starting to guarantee, however gradually.
A Free Vaccine on the Horizon
The most forward-looking development concerns the young. The HPV vaccine is set to enter Congo’s expanded immunisation programme, a move the specialists expect to strengthen prevention for the next generation of women.
It will target adolescent girls aged 12 to 14, the window when the vaccine offers the greatest protection. Crucially, it will be free, funded by the State, removing the price tag that so often keeps such tools out of reach.
Together with wider screening and broader insurance coverage, the vaccine completes a strategy taking shape in Brazzaville. The message from the city’s specialists was steady and clear. Against cervical cancer, prevention remains Congo’s best line of defence.